Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were colorectal (23), renal (21), and non small cell lung (17). No patient had received prior chemotherapy. The drug was given intravenously as a 20 min infusion at the dose of 120 mg-2 on days 1 to 5 every 3 weeks. Treatment was well tolerated; the only significant side effects being mild nausea and generalised musculo-skeletal pains. Response was assessed after two cycles of therapy. No patient achieved an objective partial response. A total of nine patients demonstrated stable disease for a median duration of 11 weeks. Using this schedule of administration, fosquidone has no significant antitumour activity in this group of tumours.

Original publication

DOI

10.1038/bjc.1992.127

Type

Journal article

Journal

Br J Cancer

Publication Date

04/1992

Volume

65

Pages

624 - 625

Keywords

Adult, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Humans, Isoquinolines, Kidney Neoplasms, Lung Neoplasms, Middle Aged, Neoplasm Metastasis, Organophosphorus Compounds